Wong Susan S W, Aboumarzouk Omar M, Narahari Radhakrishna, O'Riordan Anna, Pickard Robert
Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK.
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD006934. doi: 10.1002/14651858.CD006934.pub3.
Strictures of the urethra are the most common cause of obstructed micturition in younger men and frequently recur after initial treatment. Standard treatment comprises internal widening of the strictured area by simple dilatation or by telescope-guided internal cutting (optical urethrotomy), but these interventions are associated with a high failure rate requiring repeated treatment. The alternative option of open urethroplasty whereby the urethral lumen is permanently widened by removal or grafting of the strictured segment is less likely to fail but requires greater expertise. Findings of Improved choice of graft material and shortened hospital stay suggest that urethroplasty may be under utilised. The extent and quality of evidence guiding treatment choice for this condition are uncertain.
To determine which is the best surgical treatment for male urethral stricture disease taking into account relative efficacy, adverse event rates and cost-effectiveness.
We searched the Cochrane Incontinence Group Specialised Register (searched 21 June 2012), CENTRAL (2012, Issue 6), MEDLINE (January 1946 to week 2 June 2012), EMBASE (January 1980 to week 25 2012), OpenSIGLE (searched 26 June 2012), clinical trials registries and reference lists of relevant articles.
We included publications reporting data from randomised or quasi-randomised controlled trials comparing the effectiveness of dilatation, urethrotomy and urethroplasty in the treatment of adult men with urethral stricture disease.
Two authors evaluated trials for appropriateness for inclusion and methodological quality. Data extraction was performed using predetermined criteria. Analyses were carried out using the Cochrane Review Manager software (RevMan 5).
Two randomised trials were identified. One trial compared the outcomes of surgical urethral dilatation and optical urethrotomy in 210 adult men with urethral stricture disease. No significant difference was found in the proportion of men being stricture free at three years or in the median time to recurrence. The second trial compared the outcomes of urethrotomy and urethroplasty in 50 men with traumatic stricture of the posterior urethra following pelvic fracture injury. In the first six months, men were more likely to require further surgery in the urethrotomy group than in the primary urethroplasty group (RR 3.39, 95% CI 1.62 to 7.07). After two years, 16 of 25 (64%) men initially treated by urethrotomy required continued self-dilatation or further surgery for stricture recurrence compared to 6 of 25 (24%) men treated by primary urethroplasty. There were insufficient data to perform meta-analysis or to reliably determine effect size.
AUTHORS' CONCLUSIONS: There were insufficient data to determine which intervention is best for urethral stricture disease in terms of balancing efficacy, adverse effects and costs. Well designed, adequately powered multi-centre trials are needed to answer relevant clinical questions regarding treatment of men with urethral strictures.
尿道狭窄是年轻男性排尿梗阻最常见的原因,且初始治疗后常复发。标准治疗包括通过单纯扩张或经尿道镜引导的内部切割(光学尿道切开术)对狭窄区域进行内部扩宽,但这些干预措施的失败率较高,需要重复治疗。开放性尿道成形术作为另一种选择,通过切除或移植狭窄段使尿道腔永久性扩宽,失败可能性较小,但需要更高的专业技术。移植材料选择的改进和住院时间的缩短表明尿道成形术可能未得到充分应用。指导该疾病治疗选择的证据的范围和质量尚不确定。
考虑相对疗效、不良事件发生率和成本效益,确定治疗男性尿道狭窄疾病的最佳手术方法。
我们检索了Cochrane尿失禁小组专业注册库(2012年6月21日检索)、Cochrane系统评价数据库(2012年第6期)、MEDLINE(1946年1月至2012年6月第2周)、EMBASE(1980年1月至2012年第25周)、OpenSIGLE(2012年6月26日检索)、临床试验注册库以及相关文章的参考文献列表。
我们纳入了报告来自随机或半随机对照试验数据的出版物,这些试验比较了扩张、尿道切开术和尿道成形术治疗成年男性尿道狭窄疾病的有效性。
两位作者评估试验是否适合纳入以及方法学质量。使用预先确定的标准进行数据提取。使用Cochrane系统评价管理软件(RevMan 5)进行分析。
确定了两项随机试验。一项试验比较了210例成年男性尿道狭窄疾病患者接受手术尿道扩张和光学尿道切开术的结果。在三年时无狭窄男性的比例或复发的中位时间方面未发现显著差异。第二项试验比较了50例骨盆骨折损伤后后尿道创伤性狭窄患者接受尿道切开术和尿道成形术的结果。在最初六个月内,尿道切开术组的男性比初次尿道成形术组更有可能需要进一步手术(相对危险度3.39,95%置信区间1.62至7.07)。两年后,最初接受尿道切开术治疗的25例男性中有16例(64%)因狭窄复发需要继续自我扩张或进一步手术,而接受初次尿道成形术治疗的25例男性中有6例(24%)需要此类治疗。数据不足,无法进行Meta分析或可靠地确定效应大小。
数据不足,无法确定在平衡疗效、不良反应和成本方面哪种干预措施对尿道狭窄疾病最佳。需要设计良好、样本量充足的多中心试验来回答有关男性尿道狭窄治疗的相关临床问题。